Childhood vaccination coverage in Australia: an equity perspective.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
07 07 2021
Historique:
received: 27 01 2021
accepted: 17 06 2021
entrez: 7 7 2021
pubmed: 8 7 2021
medline: 6 8 2021
Statut: epublish

Résumé

This study describes trends in social inequities in first dose measles-mumps-rubella (MMR1) vaccination coverage in Western Australia (WA) and New South Wales (NSW). Using probabilistically-linked administrative data for 1.2 million children born between 2002 and 2011, we compared levels and trends in MMR1 vaccination coverage measured at age 24 months by maternal country of birth, Aboriginal status, maternal age at delivery, socio-economic status, and remoteness in two states. Vaccination coverage was 3-4% points lower among children of mothers who gave birth before the age of 20 years, mothers born overseas, mothers with an Aboriginal background, and parents with a low socio-economic status compared to children that did not belong to these social groups. In both states, between 2007 and 2011 there was a decline of 2.1% points in MMR1 vaccination coverage for children whose mothers were born overseas. In 2011, WA had lower coverage among the Aboriginal population (89.5%) and children of young mothers (89.3%) compared to NSW (92.2 and 92.1% respectively). Despite overall high coverage of MMR1 vaccination, coverage inequalities increased especially for children of mothers born overseas. Strategic immunisation plans and policy interventions are important for equitable vaccination levels. Future policy should target children of mothers born overseas and Aboriginal children.

Sections du résumé

BACKGROUND
This study describes trends in social inequities in first dose measles-mumps-rubella (MMR1) vaccination coverage in Western Australia (WA) and New South Wales (NSW). Using probabilistically-linked administrative data for 1.2 million children born between 2002 and 2011, we compared levels and trends in MMR1 vaccination coverage measured at age 24 months by maternal country of birth, Aboriginal status, maternal age at delivery, socio-economic status, and remoteness in two states.
RESULTS
Vaccination coverage was 3-4% points lower among children of mothers who gave birth before the age of 20 years, mothers born overseas, mothers with an Aboriginal background, and parents with a low socio-economic status compared to children that did not belong to these social groups. In both states, between 2007 and 2011 there was a decline of 2.1% points in MMR1 vaccination coverage for children whose mothers were born overseas. In 2011, WA had lower coverage among the Aboriginal population (89.5%) and children of young mothers (89.3%) compared to NSW (92.2 and 92.1% respectively).
CONCLUSION
Despite overall high coverage of MMR1 vaccination, coverage inequalities increased especially for children of mothers born overseas. Strategic immunisation plans and policy interventions are important for equitable vaccination levels. Future policy should target children of mothers born overseas and Aboriginal children.

Identifiants

pubmed: 34229652
doi: 10.1186/s12889-021-11345-z
pii: 10.1186/s12889-021-11345-z
pmc: PMC8261950
doi:

Substances chimiques

Measles-Mumps-Rubella Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1337

Références

Med J Aust. 2018 Jun 2;209(1):24-28
pubmed: 29929457
BMC Public Health. 2019 Mar 12;19(1):290
pubmed: 30866881
Aust N Z J Public Health. 2019 Jun;43(3):214-220
pubmed: 30959563
BMC Public Health. 2018 Jan 30;18(1):196
pubmed: 29378545
Vaccine. 2015 Jun 26;33(29):3377-83
pubmed: 26003493
J Epidemiol Community Health. 2017 Jan;71(1):87-97
pubmed: 27535769
Health Policy. 2020 May;124(5):511-518
pubmed: 32276852
Vaccine. 2020 Aug 27;38(38):6057-6064
pubmed: 31628032
Vaccine. 2021 Feb 5;39(6):984-993
pubmed: 33431224
Aust N Z J Public Health. 2003 Oct;27(5):533-8
pubmed: 14651401
Vaccine. 2016 May 23;34(24):2635-43
pubmed: 27109562
J Paediatr Child Health. 2011 Dec;47(12):888-92
pubmed: 22171831
Vaccine. 2019 Jan 7;37(2):219-222
pubmed: 28760612
Matern Child Health J. 2012 Apr;16(3):569-78
pubmed: 21505781
Med J Aust. 2020 Oct;213(8):364-369
pubmed: 32951230
Vaccine. 2010 Feb 17;28(7):1861-9
pubmed: 20006570
Lancet Child Adolesc Health. 2017 Sep;1(1):9-11
pubmed: 30169232
Aust N Z J Public Health. 2004 Feb;28(1):72-9
pubmed: 15108751
Int J Popul Data Sci. 2017 Sep 18;2(1):406
pubmed: 32934996
Aust N Z J Public Health. 2016 Apr;40(2):159-64
pubmed: 26559155
Commun Dis Intell Q Rep. 2010 Dec;34 Supp:S1-167
pubmed: 21416762
Vaccine. 2018 Feb 14;36(8):1055-1062
pubmed: 29395515
J Public Health Res. 2019 Mar 11;8(1):1436
pubmed: 30997357
Vaccine. 2018 Jun 27;36(28):4062-4069
pubmed: 29861181
Aust Fam Physician. 2017 Mar;46(3):145-151
pubmed: 28260278
Hum Vaccin Immunother. 2015;11(12):2895-903
pubmed: 26366978
Vaccine. 2009 Aug 13;27(37):5054-60
pubmed: 19576945
Aust N Z J Public Health. 2001 Oct;25(5):405-10
pubmed: 11688617
Vaccine. 2009 Jan 7;27(2):307-12
pubmed: 18977263
N S W Public Health Bull. 2010 Sep-Oct;21(9-10):193-5
pubmed: 21322307
J Paediatr Child Health. 2014 Apr;50(4):306-13
pubmed: 24354932

Auteurs

Arzu Arat (A)

Institute of Environmental Medicine, Unit of Occupational Medicine, Karolinska Institute, Stockholm, Sweden. arzu.arat@ki.se.

Hannah C Moore (HC)

Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Perth, WA, Australia.

Sharon Goldfeld (S)

Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia.

Viveca Östberg (V)

Department of Public Health Sciences, Stockholm University, Stockholm, Sweden.

Vicky Sheppeard (V)

Communicable Diseases Branch, Health Protection NSW, North Sydney, NSW, Australia.

Heather F Gidding (HF)

Women and Babies Research, Kolling Institute, Northern Sydney Local Health District, St Leonards, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH